Allarity Therapeutics FY2025 net loss $11.2M, cash $14.7M, stenoparib Fast Track

Allarity Therapeutics, Inc.

Net loss improved to $11.2M ($0.78/shr) from $25.1M ($15.65/shr) in 2024; first revenue of $320k.
Year-end cash $14.7M; extended runway with $20M non-convertible debt financing closed March 2026.
Stenoparib received FDA Fast Track for advanced ovarian cancer; new Phase 2 protocol implemented.
VA-funded Phase 2 combo trial (stenoparib+temozolomide) in SCLC opened at 11 VA sites; first patients dosed early 2026.
Jeff Ervin appointed CFO in July 2025 as part of leadership strengthening; DRP platform licensing initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Allarity Therapeutics, Inc. reported financial results for the fiscal year ended December 31, 2025.

Period: the fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 31, 2026, Allarity Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fiscal year ended December 31, 2025.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Allarity Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-038061

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.